Sierra Oncology Inc (OQ:SRRA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 2150-885 Georgia St W
Tel: N/A
IR: See website
Key People
Donald R. Parfet
Independent Chairman of the Board
Nicholas R. Glover
President, Chief Executive Officer, Director
Sukhi Jagpal
Chief Financial Officer
Barbara Klencke
Chief Development Officer
Mark Kowalski
Chief Medical Officer
Angie J. You
Chief Business & Strategy Officer and Head of Commercial
Business Overview
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company's lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company's SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
Financial Overview
For the three months ended 31 March 2018, Sierra Oncology Inc revenues was not reported. Net loss increased 4% to $11.5M. Higher net loss reflects Research and development increase of 4% to $8.3M (expense), General and administrative increase of 9% to $3.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.26 to -$0.19.
Employees: 53 as of Dec 31, 2016
Reporting Currency: U.S. Dollars
Enterprise value: $44.52M as of Mar 31, 2018
Annual revenue (TTM): $0.00M as of Mar 31, 2018
EBITDA (TTM): -$42.94M as of Mar 31, 2018
Net annual income (TTM): -$35.25M as of Mar 31, 2018
Free cash flow (TTM): -$37.42M as of Mar 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 74,311,481 as of May 8, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization